Pandion, Astellas team up on immunomodulators for pancreatic diseases
Category: #health  By Mateen Dalal  Date: 2019-10-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pandion, Astellas team up on immunomodulators for pancreatic diseases

Pandion Therapeutics, Inc. and Astellas Pharma Inc. have reportedly inked a license and collaboration deal for researching, developing and commercializing pancreas-targeting immunomodulators.

The companies will work on locally acting immunomodulators for pancreatic autoimmune diseases, by combining the advanced therapeutics development and commercialization expertise of Astellas with functional immunology and modular biologics capabilities of Pandion. Pandion is slated to receive around $45 million in upfront and further payments associated with research and preclinical work.

According to the terms of the deal, Pandion would be designing and discovering bispecific drug candidates, based on the company’s proprietary immune effector and tissue tether platform. On the other hand, Astellas will conduct preclinical activities, clinical studies and be responsible for commercialization activities for the specific candidates developed through the partnership.

In case Astellas is able to develop and commercialize several candidates for multiple autoimmune diseases of the pancreas, Pandion could be awarded over $750 million by Astellas as future development and commercial milestone achievements. For any product developed under the partnership, Pandion is eligible to earn royalties on global net sales as well.

Astellas’ CSO and CFO, Naoki Okamura said that antigen-specific immune modulation (ASIM) is among the strategic fields being focused on primarily, and the company is involved in developing innovative treatments for autoimmune diseases through new technologies.

The tissue-specific immune modulation technology of Pandion is expected to be a possible next-gen ASIM modality, that could help expand it application scope to other autoimmune diseases, Okamura added.

According to Rahul Kakkar, MD, Pandion CEO, Astellas is a partner having a strategic vision for the capabilities of local immunomodulation in Type 1 diabetes and significant commitment towards immunology. It will help boost Pandion’s R&D activities and build upon its existing partnership with the JDRF T1D Fund.

Kakkar mentioned that in Type 1 diabetes, patient’s pancreas undergo autoimmune destruction. Pandion’s tissue targeted immune effectors aim to address this immune response directly, modifying the diseases and the site of the immune attack.
 

Source Credits: https://www.astellas.com/en/news/15396

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

British Airways suspends 30,000 employees amid growing COVID-19 crisis
British Airways suspends 30,000 employees amid growing COVID-19 crisis
By Mateen Dalal

British Airways, a renowned British airline, has reportedly reached a new agreement with unions according to which over 30,000 ground staff and cabin crew members would be suspended. This is the most dramatic move ever to take place in the commercial...

Bunnings Warehouse launches a range of fitness equipment online
Bunnings Warehouse launches a range of fitness equipment online
By Mateen Dalal

The retail giant will be selling equipment like rowing machine, treadmills, cross trainers, and exercise bikes starting at $349. Bunnings Warehouse, an Australian household hardware chain, has reportedly launched an affordable range of fit...

Home Depot to reserve masks for frontline healthcare professionals
Home Depot to reserve masks for frontline healthcare professionals
By Mateen Dalal

As COVID-19 cases continue to soar in America, medical professionals on the front lines are facing a shortage of masks and other protective equipment. To cope up with increasing demand, The Home Depot Inc., one of the leading home improvement retaile...